Clinical trial
A Prospective Phase II, Randomized Multi-center Trial of a Combined Modularized Treatment With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Nivolumab in Patients With Squamous Cell Lung Cancer and Non- Squamous Cell Lung Cancer, Respectively After Platin Failure
NCT02852083 is registered in ClinicalTrials.gov with University Hospital Regensburg as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Phase II, Randomized Multi-center Trial of a Combined Modularized Treatment With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Nivolumab in Patients With Squamous Cell Lung Cancer and Non- Squamous Cell Lung Cancer, Respectively After Platin Failure
- Lead sponsor
- University Hospital Regensburg
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- January 31, 2016
- Completion date
- July 31, 2020
- Enrollment
- 86 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
non-small cell lung cancer, non-squamous cell lung cancer, squamous cell lung cancer